Videos

Annette Okai, MD, FAAN, discusses how she is utilizing the newer oral therapies and treatment advances in her practice.

Two MS experts discuss how the field is benefiting from availability of real-world data, given the absence of head-to-head trials.

The professor of neurology at the University of Saskatchewan discussed the need to improve therapeutics aimed at improving neurodegeneration in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Bradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.

Experts in headache medicine review novel therapeutic agents under investigation and the evolving treatment landscape for migraine.

Rajesh Pahwa, MD; Robert A. Hauser, MD, MBA; and Laxman Bahroo, DO, provide insight on the challenges with motor and nonmotor symptoms of OFF episodes for patients with Parkinson Disease.

Drs Rajesh Pahwa, Robert A. Hauser, and Laxman Bahroo assess the awareness of OFF episodes in patients with Parkinson Disease and comment on improving education and awareness among non-neurology clinicians and other health care providers.

The professor of neurology at the University of Saskatchewan discussed his presentation at the 2022 CMSC Annual Meeting on using ribonucleoprotein A1 antibodies to drive neurodegeneration in multiple sclerosis. [WATCH TIME: 4 minutes]

Rajesh Pahwa, MD; Laxman Bahroo, DO; and Robert A. Hauser, MD, MBA, examine the impact of OFF episodes on patients and their families’ quality of life and discuss goals of therapy for Parkinson Disease.

The founder and chief medical officer of Omniscient Neurotechnology commented on the areas of need with understanding the brain map and treating conditions with multiple pathway crossover. [WATCH TIME: 4 minutes]

The professor of neurology at MedStar Georgetown University Hospital shared his perspective on the trends in thinking about the treatment of MS and how an improved understanding of underlying processes has led to a shift in the field. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending May 28, 2022.

Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.

Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.

The chief of emergency medical services at Jefferson Health spoke about the operation of the Jefferson mobile stroke unit in the field, and the impact that the onset of the COVID-19 pandemic had on launching the program. [WATCH TIME: 3 minutes]

Drs Obeidat and Okai discuss long-term data with oral DMTs that were recently presented at ACTRIMS 2022.

MS experts highlight the value of monitoring and use of risk mitigation strategies when taking care of patients with MS.

The director of the Stanford Stroke Center and Coyote Foundation Professor of Neurology and Neurological Sciences at Stanford Medical Center shared his perspective on the uptake of mobile stroke units across the United States. [WATCH TIME: 6 minutes]

Julio R. Vieira, MD, leads a discussion on the importance of follow-up visits for patients with migraine and considerations for switching therapies.

Andrew C. Charles, MD; Bradley Torphy, MD; and Jessica Ailani, MD, review current FDA approved CGRP monoclonal antibodies available for the preventive treatment of migraine.

Robert A. Hauser, MD, MBA, discusses the appearance of OFF episodes throughout progression of Parkinson disease.

Laxman Bahroo, DO, and Rajesh Pahwa, MD, comment on the identification and presentation of OFF episodes in patients with Parkinson disease.

The executive director of the Bensalem Rescue Squad spoke specifically to how the MSU has shifted the paradigm of care that EMS can provide to individuals in the community. [WATCH TIME: 4 minutes]

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]

The founder and chief medical officer of Omniscient Neurotechnology provided insight on the successes using connectomics, including the FDA approval of Quicktome, a digital brain mapping platform. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.

Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.

The founder and chief medical officer of Omniscient Neurotechnology discussed the idea behind connectomics and how AI revolutionizes large-scale brain data. [WATCH TIME: 4 minutes]